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Abstract
This review integrates eight aspects of cerebrospinal fluid (CSF) circulatory dynamics: formation
rate, pressure, flow, volume, turnover rate, composition, recycling and reabsorption. Novel ways
to modulate CSF formation emanate from recent analyses of choroid plexus transcription factors
(E2F5), ion transporters (NaHCO3  cotransport), transport enzymes (isoforms of carbonic
anhydrase), aquaporin 1 regulation, and plasticity of receptors for fluid-regulating neuropeptides. A
greater appreciation of CSF pressure (CSFP) is being generated by fresh insights on peptidergic
regulatory servomechanisms, the role of dysfunctional ependyma and circumventricular organs in
causing congenital hydrocephalus, and the clinical use of algorithms to delineate CSFP waveforms
for diagnostic and prognostic utility. Increasing attention focuses on CSF flow: how it impacts
cerebral metabolism and hemodynamics, neural stem cell progression in the subventricular zone,
and catabolite/peptide clearance from the CNS. The pathophysiological significance of changes in
CSF volume is assessed from the respective viewpoints of hemodynamics (choroid plexus blood
flow and pulsatility), hydrodynamics (choroidal hypo- and hypersecretion) and neuroendocrine
factors (i.e., coordinated regulation by atrial natriuretic peptide, arginine vasopressin and basic
fibroblast growth factor). In aging, normal pressure hydrocephalus and Alzheimer's disease, the
expanding CSF space reduces the CSF turnover rate, thus compromising the CSF sink action to
clear harmful metabolites (e.g., amyloid) from the CNS. Dwindling CSF dynamics greatly harms the
interstitial environment of neurons. Accordingly the altered CSF composition in neurodegenerative
diseases and senescence, because of adverse effects on neural processes and cognition, needs more
effective clinical management. CSF recycling between subarachnoid space, brain and ventricles
promotes interstitial fluid (ISF) convection with both trophic and excretory benefits. Finally, CSF
reabsorption via multiple pathways (olfactory and spinal arachnoidal bulk flow) is likely
complemented by fluid clearance across capillary walls (aquaporin 4) and arachnoid villi when CSFP
and fluid retention are markedly elevated. A model is presented that links CSF and ISF homeostasis
to coordinated fluxes of water and solutes at both the blood-CSF and blood-brain transport
interfaces.
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11 Conclusion
1 Overview
Free-flowing cerebrospinal fluid (CSF) finely-regulated in
composition is vital to brain health [1,2]. Aging- or dis-
ease-induced alterations in CSF circulation adversely
impact neuronal performance [2,3]. Throughout life the
choroid plexus (CP)-CSF dynamics are damaged by
tumors, infections, trauma, ischemia or hydrocephalus [4-
8]. Severely disrupted CSF flow disturbs cognitive and
motor functions [9]. CNS viability is taxed if key choroi-
dal-CSF parameters are distorted. For health and disease it
is essential to delineate interactions of CP and brain with
the intervening CSF (Fig. 1).
Improved biotechnology and models can now precisely
evaluate the role of the CP-CSF in modulating brain devel-
opment, metabolism and aging [10-12]. Alternative trans-
plant [13-15] and pharmacological strategies [16-18]
utilizing the CP may be helpful in rescuing the debilitated
CSF system. Such therapy to rectify CSF parameters would
ultimately benefit neuronal network functions. This
Morphology of blood-brain-CSF interfaces: (A) Schema of main CNS compartments and interfaces Figure 1
Morphology of blood-brain-CSF interfaces: (A) Schema of main CNS compartments and interfaces. The blood-brain and 
blood-CSF barriers are true barriers with tight junctions between endothelial and epithelial cells, respectively. The brain-CSF 
interface, because of gap junctions between ependymal (or pia-glial) cells, is more permeable than brain or spinal cord capillar-
ies and choroid plexus. (B) Blood-CSF barrier. CP is comprised of one cell layer of circumferentially arranged epithelial cells. 
Plexus capillaries, unlike counterparts in brain, are permeable to macromolecules. (C) Blood-brain barrier: Endothelial cells are 
linked by tight junctions, conferring low paracellular permeability. Endothelial cell pinocytotic vesicle paucity reflects minimal 
transcytosis. (D) Brain-CSF interface: Ependymal lining in lateral ventricles permits relatively free diffusion of solutes between 
brain ISF and large-cavity CSF. Motile cilia at ependymal cell apex move CSF downstream to SAS. Reprinted with permission 
from Advanced Drug Delivery Reviews [17].Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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review sets forth new approaches to stabilize the CSF in
disease or curb its deterioration in late-life stages [19].
CSF assessment should collectively consider physical, bio-
chemical and physiological parameters (Table 1). In addi-
tion, the large-cavity CSF system is multi-compartmental
(Fig. 2). Ventricles, cisterns and subarachnoid space (SAS)
are serially linked. Upstream CSF transport phenomena
exert effects downstream. Ventricular CSF is functionally
interactive with the ependymal wall [1] as well as the
more deeply-lying brain capillary surfaces [16,17]. Diffu-
sion and bulk flow promote solute and water distribution
both into and out of brain, depending upon prevailing
regional gradients for concentration and hydrostatic pres-
sure in various compartments (Fig. 1). It is thus pertinent
to analyze CNS fluid spaces- how they are disrupted by
ventricular dysfunction and might be modified by CSF-
borne therapeutic agents. This should promote transla-
tional steps for managing CSF in neurodegenerative dis-
eases and other disorders.
2 CSF formation
Several CNS regions form CSF or a CSF-like fluid.
Although CP tissues generate about two thirds of the total
production, extrachoroidal sources make up the balance
[20]. The capillary-astrocyte complex in the blood-brain
barrier (BBB) has been implicated as an active producer of
brain interstitial fluid (ISF) [21], but normally at a rate
substantially slower (1/100 when normalized for barrier
surface area) than the blood-cerebrospinal fluid barrier
BCSFB [22]. The working hypothesis that the BBB is a
fluid generator, although attractive, needs substantiation.
Another likely source of CSF, according to Pollay and
Curl, is the ependyma lining the ventricles [23]. The
arachnoid membrane with its relatively large surface area,
although secreting peptides and proteins [24], probably
does not actively form CSF. Because CP rapidly produces
most of fluid within the CNS and has been extensively
documented for CSF-forming capabilities [1], the discus-
sion below focuses on choroidal epithelium.
Originating in the ventricular interior of the brain, nas-
cent CSF is continuously produced by the CPs in the lat-
eral, 3rd and 4th ventricles. Because CNS metabolism is
profoundly affected by CSF transport, it is imperative to
delineate the physiological and molecular processes in CP
that effect CSF secretion. CSF formation occurs in two
stages: passive filtration of fluid across choroidal capillary
endothelium [25], followed by a regulated active secre-
tion across a single-layered epithelium (Fig. 3). Scores of
investigations have characterized solute movement from
blood to CSF by diffusion, facilitated transport and active
transport. Such studies elucidate the nature and unique-
ness of fluid transfer across the BCSFB.
Fluid is generated at a high capacity by the choroid plexus
epithelial (CPe) cells [1]. The CPe secretory engine is
fueled by a brisk arteriolar input of organic substrates and
water to the extensive capillary plexus [1]. A blood flow of
about 4 ml/min/g CP is converted to a CSF formation in
mammals of approximately 0.4 ml/min/g. The smallest
mammalian species in which formation rate has been
quantified is the mouse which produces CSF at 3.3 × 10-4
ml/min [26]. If one extrapolates animal data to humans
on the basis of CSF produced per volume of brain tissue,
human CSF production should be about 0.8 ml/min.
Measurements to date, however, show that human CSF
production is roughly one-half that rate [3].
CSF formation begins as plasma is filtered across permea-
ble choroidal capillaries [25]. Net filtration is propor-
tional to the hydrostatic pressure gradient between blood
Table 1: Physico-chemical properties and physiological parameters of the CSF system
CSF Formation Rate Produced mainly by choroid plexuses, CSF is formed at 0.4 ml/min/g in several mammals. Human production rates vary from 0.3 to 0.6 ml/min 
depending upon measurement method. CSF formation, an active secretion by epithelial cells, involves pumps, cotransporters & antiporters, ion 
channels and aquaporins [1, 77]. It is under neuroendocrine & hormonal modulation [6, 246]. Daily volume of CSF produced in adult humans is 
500–600 ml.
CSF Pressure In adult humans the normal CSFP is about 100 mm H2O. Ventricular pressure is normally about 35 mm H20 in rats. CSFP is typically slightly higher 
than venous pressure in the dural sinuses. CSFP is stable when CSF formation and reabsorption are balanced. Elevated CSFP is reduced by 
acetazolamide, which inhibits formation of fluid by the choroid plexus [36, 43, 44].
CSF Flow Flow of CSF is pulsatile [185, 192]. CSF pulsations depend upon the arterial hemodynamics in the plexus. CSF flow is from the lateral to 3rd and 4th 
ventricles. CSF flows out of 4th ventricular foramina into basal cisterns [1]. It is then convected into the spinal and cortical subarachnoid spaces.
CSF Volume In healthy humans, the ventricular and subarachnoid CSF spaces, respectively, are about 25% and 75% of total CSF volume [1]. Total CSF space in 
young adults is about 160 ml, i.e., more than half that of brain interstitial fluid volume. The ratio of CSF volume to brain volume increases in aging 
and neurodegeneration [9, 19].
CSF Turnover Rate CSF turnover rate is directly proportional to CSF formation rate and inversely related to CSF volume [3]. It is an index of CSF sink action on brain 
interstitial solutes [33]. Clearance of brain metabolites depends on a CSF renewal of 0.3–0.4% per min. Mammalian CSF is totally replaced about 4 
times each day.
CSF Composition CSF is an active secretion, not simply a plasma ultrafiltrate [1]. Carrier transport of ions and molecules, along with molecular sieving at blood-CSF 
barrier, generates a CSF concentration lower than plasma in protein, K [221] & urea [33]; and higher in Cl & Mg. Disease distorts CSF chemistry, 
enabling CSF biomarking [227]. CSF is 99% water, compared to the 92% water of plasma.
CSF Recycling In addition to CSF macrocirculation through ventriculo-subarachnoid spaces, there is limited microcirculation of CSF recirculated by bulk flow from 
the cortical subarachnoid space into Virchow-Robin perivascular spaces and then out of brain via CSF drainage routes [253–255].
CSF Reabsorption CSF is cleared from CNS by bulk flow along sleeves of the subarachnoid space surrounding cranial nerves that enter the nose and eyes [263, 264]. 
Substantial drainage occurs through the cribriform plate, the CSF eventually reaching the nasal submucosa and downstream cervical lymphatics 
[267, 268]. CSF is also cleared along spinal nerves [279]. Lymphatic drainage of CSF needs substantiation in humans. Arachnoid villi in dural venous 
sinuses may serve as ancillary drainage sites when CSFP is elevated.Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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and choroid interstitial fluid (ISF). Normally, in accord
with Starling's law of filtration, fluid flows freely from
plasma into ISF at the basolateral surface of the epithelial
cells. Reduced blood flow to the plexus, via rate-limited
tissue perfusion, curtails plasma filtration into the intersti-
tium. Consequently in acute hydrocephalus the substan-
tially elevated ventricular CSF pressure, when retrogradely
transmitted to choroidal ISF, reduces plasma exudation
into ISF. This decreases CSF formation. However with nor-
mal choroidal perfusion and CSF hydrodynamics, a con-
tinual stream of plasma ultrafiltrate (ions and water) is
presented for fluid manufacture to transporters at the
basolateral side of the epithelium.
Transchoroidal secretion of water, ions and macromole-
cules drives the volume transmission of CSF (Fig. 2) down
the ventriculo-cisternal axis [27]. Actively formed CSF
stems from coordinated secretion of solutes across the
thin epithelial interface (Fig. 3) between the inner choroi-
dal plasma and outer ventricular fluid. The CP epithelium
is polarized both structurally (Fig. 3) and functionally
(Figs. 4 and 5). Pharmacological modeling of CSF dynam-
ics is necessarily built on foundational knowledge of
plexus blood flow as well as epithelial metabolism and
transport (Fig. 5).
CSF formation involves an intricate array of transporters
and channels in CPe. Salient elements of this complex
process deserve highlighting. Accordingly, Fig. 4 schemat-
ically illustrates how choroid epithelial polarity (sided-
ness) relates to transcellular movement of solutes across
the BCSFB. Although bidirectional transport of ions
occurs at both poles of choroid epithelial cells, CSF forma-
tion is essentially the net transport of Na+, Cl-, K+, HCO3
-
and water from plasma to CP to CSF (Fig. 4A). Ions and
water are taken up by facilitating mechanisms at the baso-
lateral membrane, convected through cytoplasm, and
then released or actively secreted into the ventricles on the
apical side. Vectorially, favorable electrochemical gradi-
ents (energetically downhill) exist for Na+  movement
inward at the plasma side and for K+, Cl- and HCO3
- diffu-
sion outward at the CSF side (Fig. 4B). Facilitated water
flux via aquaporin (AQP) channels osmotically balances
the collective ion transport and furnishes the medium for
CSF circulation.
Ultrastructure of choroid epithelium Figure 3
Ultrastructure of choroid epithelium. CP from a lateral 
ventricle of an untreated adult Sprague-Dawley rat was fixed 
for electron microscopy with OsO4. There is a profusion of 
apical membrane (CSF-facing) microvilli (Mv) and many intra-
cellular mitochondria (M). J refers to the tight junction weld-
ing two cells at their apical poles. C = centriole. G and ER, 
Golgi apparatus and endoplasmic reticulum. Nucleus (Nu) is 
oval and has a nucleolus. Arrowheads point to basal lamina at 
the plasma face of the epithelial cell; the basal lamina sepa-
rates the choroid cell above from the interstitial fluid below. 
Basal labyrinth (BL) is the intertwining of basolateral mem-
branes of adjacent cells. Choroidal morphology resembles 
proximal tubule, consistent with both cell types rapidly turn-
ing over fluid. Scale bar = 2 μm.
Large-cavity CSF compartments and bulk flow Figure 2
Large-cavity CSF compartments and bulk flow. Extra-
cellular fluid enables volume transmission (convection) of 
fluid from ventricles to SAS [7, 27]. CSF formed by lateral, 
3rd and 4th ventricle CPs flows from the lateral to 3rd ventricle 
via the cerebral aqueduct and 4th ventricle to SAS in cisterna 
magna. Then CSF is transmitted by bulk flow through cister-
nal foramina (Magendie and Luschka) into basal cisterns. CSF 
is also convected from ventricles through velae channels to 
the quadrigeminal and ambient cisterns [167]. Thereafter 
fluid is convected to the SAS of the spinal cord and brain 
convexities. As CSF flows through the ventriculo-subarach-
noid system, there are diffusional and bulk flow exchanges 
between CSF and brain [16, 24, 168, 169, 289], depending 
upon region-specific gradients for concentration and hydro-
static pressure that promote widespread distribution of CSF-
borne materials [255]. Normally CSF is readily distributed 
from the ventricles to arachnoidal drainage sites. In hydro-
cephalus, flow pathways can be disrupted at multiple points.Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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CSF generation is a cardinal feature of brain fluid home-
ostasis [1]. To finely control the CSF formation rate is a
challenge in treating diseases related to brain fluid disor-
ders. Historically, emphasis has been placed on discover-
ing new agents to relieve elevated CSF pressure (CSFP),
i.e., intracranial pressure (ICP), in pediatric hydrocepha-
lus patients. Projections point to the additional compel-
ling need for increasing CSF turnover rate in geriatric
patients, since many are taking diuretics and digitalis
preparations that reduce CSF formation. This implicates a
wider spectrum of CSF pharmacology. To individualize
therapy for normal-pressure and high-pressure hydro-
cephalus, there should be a drug repertoire for up- and
down-regulating CSF formation rates.
Pharmacological targeting to modify CSF production by
the CP will advance as cellular mechanisms are eluci-
dated. To date, acetazolamide and furosemide are among
only a few agents that have had clinical usefulness in con-
trolling CSF formation and ICP, but side effects limit their
usage [28,29]. Clearly, new agents are needed to restore
CSF dynamics altered by disease and injury. Theoretically,
nuclear, cytoplasmic and plasma membrane constituents
are potential sites for drug actions to accelerate or reduce
CSF production. Transcription factors in the nucleus,
enzymes in the cytoplasm, and transporters/channels and
receptors at the limiting plasma membrane are all poten-
tial drug targets. Five approaches to modify CSF formation
rate, i.e., cutting-edge as well as established, are recapitu-
lated in Table 2 and elaborated below:
2.1 Transcription factors
Traditionally CSF formation has been experimentally
altered by interfering with membrane ion transporters or
by reducing delivery of substrate. Nevertheless, metaboli-
cally upstream molecular manipulations for modulating
CSF secretion deserve consideration. A novel approach is
to target transcription factors as putative regulators of cel-
lular enzymes in CSF formation. Mice lacking the tran-
scription factors p73, foxJ1 and E2F5 develop non-
obstructive hydrocephalus [30,31], possibly from CSF
over secretion. Epithelial ultrastructure analysis and elec-
tron translucence in micrographs are consistent with
accelerated fluid formation by CP [32]. It is intriguing that
E2F5 in CPe is down-regulated as the cells mature (i.e. as
they convert from pseudostratified to single cuboidal epi-
thelium) in their ability to produce CSF [30]. Such
ontogenetic findings on transcription factors in mice and
human CP [30,31] prompt a new tack to augment CSF for-
mation by manipulating E2F5 expression.
Releasing the natural inhibitory brake on the manufacture
of CSF would be a unique way to increase fluid transfer
across CP. There is an experimental precedent for this the-
oretical approach. Resection of the sympathetic nerve
from the superior cervical ganglion attenuates the inhibi-
tory autonomic tone on CP. This increases CSF produc-
tion [32]. Enhancing CSF formation and the associated
sink action [33] on brain interstitial solutes may find
application to aging, normal pressure hydrocephalus
(NPH), and Alzheimer's disease (AD) patients who retain
extracellular metabolites from sluggish fluid turnover
[19].
2.2 Ion transporters
Most attempts to regulate CSF formation rate have been
directed at altering ion movement via transporters in the
basolateral (plasma-facing) and apical (CSF-facing) mem-
branes of the CPe [1]. Because the CP is a kidney-type
organ [34], with epithelial mechanisms [35] similar to
those in the renal tubule that transfer a large volume of
ions and water, many diuretic agents have been tested for
Mechanisms of CSF formation: Net ion transport and elec- trochemical gradients A Figure 4
Mechanisms of CSF formation: Net ion transport and 
electrochemical gradients A. CSF secretion by CP is by net 
transport of Na+, K+, Cl-, HCO3
- and water, from plasma to 
ventricles. Reabsorptive ion fluxes CSF to blood occur simul-
taneously with active secretion but overall, there is net 
movement of ions and water into ventricles. CSF osmolality 
resembles plasma. B. Na+ moves down a concentration gradi-
ent via secondary active transport (e.g., Na+-H+ exchange) in 
the basolateral membrane (Fig. 5) [38, 43]. K+, Cl- and HCO3
- 
diffuse down their electrochemical gradients [38] via ion 
channels in apical membrane [50] (Fig. 5). Arrow for Na+ 
symbolizes a steep inward concentration and electrochemical 
gradient [38]. For K+, Cl- and HCO3
-, the respective arrows 
depict outwardly-directed electrochemical gradients pro-
moting ion diffusion via channels into CSF [50]. Choroidal 
cell concentrations (mM) for Na+, K+, Cl- and HCO3
-, respec-
tively, are about 48, 145, 65, and 9.5 for rat [38]. The poten-
tial difference across the CPe membranes is 45–50 mV, CSF 
being about 5 mV positive to plasma at pH 7.4.
PLASMA CSF
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GRADIENTS FOR IONS
CSF
HCO3
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ability to inhibit CSF formation [1,27]. Gaining insight on
the many ion transporters and channels in CPe is key to
attaining fine control of CSF production, upward as well
as downward regulation.
At the basolateral membrane, the uptake of Na+ and Cl- is
the primary step in CSF formation (Fig. 5). Inward trans-
port of fixed ions, Na+ and Cl-, is facilitated by carriers
functionally dependent upon basolateral transmembrane
gradients for Na+, Cl-, H+ and HCO3
-. The basolateral Na+-
H+ exchanger (NHE1) transfers Na into the choroid cell.
This process is inhibited by the diuretic agent amiloride
[36-38], which decreases CSF formation [36,38]. This
action is analogous to the polyuria caused by inhibiting
the proximal and distal tubule Na+-H+ exchanger (NHE3)
that normally supports substantial fluid transfer in kidney
[39]. The Cl--HCO3
- exchanger translocates interstitial Cl-
into the cytoplasm. Moreover the basolateral Na+-depend-
ent Cl--HCO3
-  exchanger and the Na+-HCO3
-  cotrans-
porter in CPe [40-42] may also be potential targets for
controlling fluid movement. Na+ coupling to HCO3
- trans-
port is likely integral to nascent CSF generation [43,44].
Systemic metabolic alkalosis, in comparison to metabolic
acidosis, promotes Na+ influx into CPe and subsequently
into ventricular CSF [38]. Therefore basolateral HCO3
-
transport [40,42] by one or more mechanisms (Fig. 5)
might be manipulated to modify HCO3
- flux or alter
choroid cell pH to modulate fluid formation.
Ion transporters and channels in mammalian choroidal epithelium Figure 5
Ion transporters and channels in mammalian choroidal epithelium. Typical CPe is schematized to localize transporters and channels that trans-
fer ions and water [290]. CSF secretion results from coordinated transport of ions and water from basolateral membrane to cytoplasm, then sequentially 
across apical membrane into ventricles. On the plasma-facing membrane is parallel Na+-H+ and Cl--HCO3
- exchange [38] bringing Na+ and Cl- into cells in 
exchange for H+ and HCO3
-, respectively. Also basolaterally located is Na+-HCO3
- cotransport (NBCn1) [41] and Na-dependent Cl--HCO3
- exchange [42] 
that modulate pH and perhaps CSF formation. Apical Na+ pumping [49, 110] maintains a low cell Na+ that sets up a favorable basolateral gradient to drive 
Na+ uptake. Na+ is extruded into CSF mainly via the Na+ pump [110] and, under some conditions, the Na+-K+-2Cl- cotransporter [46]. K+-Cl- cotransport 
helps maintain cell volume [50]. Apical channels facilitate K+, Cl- and HCO3
- diffusion into CSF [68]. Aquaporin 1 channels on CSF-facing membrane [77] 
mediate water flux into ventricles. Polarized distribution of carbonic anhydrase (c.a.) and Na+-K+-ATPase [51], and aquaporins, enable net ion and water 
translocation to CSF.
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At the apical membrane Na+-K+-ATPase, the Na pump, is
a workhorse that actively secretes Na into the ventricles
(Fig. 5) thereby driving CSF formation. The Na pump crit-
ically keeps cell Na low [38] to set up a driving force (favo-
rable gradient) for basolateral inward Na movement via
the Na-cotransporters. Therefore, pharmacological dis-
ruption of the apical Na pump, by distorting transmem-
brane ion gradients, secondarily disables transport activity
at the opposite basolateral face. The apically located Na+-
K+-2Cl- cotransporter (NKCC1) is significant in regard to
bidirectional transport capability. The ability of the
cotransporter to transfer ions in both the secretory and
reabsorptive modes [45] reflects a versatile transporter for
regulating cell ion homeostasis and CSF dynamics. Inter-
ference with NKCC1 activity by bumetanide [46] or furo-
semide reduces CSF formation rate [47]. In both
congenital [48] and aging [18] disorders, altered expres-
sion of NKCC1 in CPe is associated with diminished CSF
formation rate. Drugs used in the aging population, e.g.,
the loop-diuretic furosemide and the cardiac glycosides
(that inhibit the choroidal Na+ pump [49]), reduce CSF
formation rate and may therefore exacerbate the deleteri-
ous effects of advanced age on the brain. Research is
needed to address how apical membrane transporters, as
well as ion channels for K+, Cl- and HCO3
- [50], can be
manipulated to increase or decrease CSF formation rate,
depending upon specific clinical needs.
2.3 Enzymes that modulate transport
In experimental settings, Na+-K+-ATPase and carbonic
anhydrase (c.a.) are the two enzymes in the CPe that have
been the most extensively analyzed in inhibitory studies
of CSF formation. Na+-K+-ATPase, or the Na+ pump, is
atypically (amongst epithelia) located on the luminal or
CSF face of the CPe. Therefore ouabain inhibits the Na+
pump (which is integral to CSF formation) when placed
intraventricularly, but not intravenously. In addition to
interfering with CSF production, the Na+-K+-ATPase inhi-
bition also alters CPe volume, potential difference and
ion homeostasis [51]; therefore, ouabain and other car-
diac glycosides have limited value in regulating human
CSF formation. On the other hand, the inhibition of c.a.
by acetazolamide is not as harsh on CPe function, and so
can be used therapeutically to reduce CSF generation.
Because a variety of c.a. isoforms is expressed in CP, there
are potentially multiple targets at the blood-CSF interface
for regulating fluid dynamics.
Ubiquitous enzymes in the c.a. group integrate cellular
acid-base phenomena with CSF formation [52]. One of
the earliest, but still clinically useful, means for decreasing
CSF formation is to reduce the intracellular generation of
labile ions (e.g., protons and bicarbonate) that feed fluid
transporters at the plasma- and CSF-facing poles of the
CPe. Cytosolic c.a. II catalyzes cellular hydration of CO2 to
yield H+ and HCO3
-. Acetazolamide, a sulfonamide drug,
slows down this reaction [44]. Consequently this elevates
choroidal cell pH, thus reducing H+ availability to basola-
teral Na+-H+ exchange [43,53,54]. Membrane-bound iso-
forms of c.a. (e.g., c.a. VIII) are likely proximate to
basolateral HCO3
- transporters (e.g., anion exchanger 2 or
AE2) to which they supply HCO3
- for exchange with inter-
stitial Cl- [55]. It is worthwhile seeking non-sulfonamide
agents to selectively inhibit specific c.a. isoforms, II, VIII
and XII [56-58]. Identifying a drug for a specific line of
attack [59] may help to reduce systemic side effects that
attend chronic acetazolamide administration.
Disruption of cellular acid-base balance by diminishing
c.a. activity with acetazolamide provides deductive
insights on the function of transporters and aquaporins.
CPe pHi increases by 0.3 – 0.4 pH units after acute expo-
sure (1 hr) to acetazolamide [43,53]. Chronic administra-
tion of acetazolamide markedly alters CP function and
structure [60], including the apical microvilli which con-
tain the AQP1 channels. In the kidney, and in the testis
(another barrier tissue), acetazolamide down-regulates
AQP1 expression [61-64], possibly by way of pHi change.
With regard to fluid transfer in the kidney, the crucial
importance of Na+-H+ antiport exchange (via NHE3) and
pHi stability for maintaining intact AQP2 and NKCC2 sys-
tems is revealed in NHE3-knockout analyses [39]. In the
physiologically analogous CPe, the coordination of mul-
tiple transporter systems (NHE1 and NKCC1) with AQP1
Table 2: Strategies for pharmacologically manipulating the rate of CSF formation by the epithelial cells of choroid plexus
- Modulation of transcription factors or nuclear receptors that control expression of enzymes involved in CSF formation
Molecular targets: p73, foxJ1, and E2F5 [30, 31]
- Interference with the basolateral and apical membrane-associated ion translocaters (cotransporters, exchangers and pumps)
Molecular targets: Na-K-Cl cotransporter [45–48]; Na-H exchanger [36–38]; Cl-HCO3 exchanger [40, 55]; Na pump [49, 106, 107, 110] Na-
HCO3 cotransporter [41]; Na-dependent Cl-HCO3 exchanger [42] K and anion channels in apical membrane [68]
- Inhibition of the enzymatic generation of labile ions in cytoplasm and in microdomains of the plasma membrane
Molecular targets: carbonic anhydrase isoforms [43, 44, 52, 53, 56–58]
- Regulation of the expression and activity of aquaporin water-conducting channels in the apical (CSF-facing) plasma membrane
Molecular target: Aquaporin 1 channel [65–68, 70–78, 292]
- Stimulation of plasma membrane receptors for fluid-regulating neuropeptides
Molecular targets: V1 receptor [83, 84, 90, 207, 210, 217]; NPR receptors [85, 97, 101, 103]; AT1 receptor [217]Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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channel function evidently allows CPe ion and volume
homeostasis to occur simultaneously with CSF secretion
[38].
2.4 Aquaporins or water channels
Yet another potential avenue for regulating CSF formation
exploits the expression plasticity of aquaporins (AQP) in
CP [65,66]. Aquaporin channels, which facilitate water
diffusion across the blood-CSF interface [67-69], appear
in the developing CPe [70,71] and are retained through-
out life. AQP1, initially designated as CHIP28 [72], is
heavily expressed at the ventricular-facing membrane of
CPe [73,74] but not in blood-brain barrier (BBB)
endothelium. Thus by regulatory phosphorylation or
ubiquitination of AQP1 [75], it may be possible to selec-
tively modulate water movement from blood into the cer-
ebral ventricles [76]. In AQP-1 null mice, there is a
substantial reduction in CSF forming-capacity of the CP;
and consequently, an associated lowering of the CSFP
[77,78]. Such knock-out studies imply that the number of
AQP1 channels in CPe apical membrane importantly
determines CSF manufacturing ability.
Of significance to CSF dynamics, nature performs an
experiment in which there is AQP1 deficiency in late life
[57]. Thus, aged (20-mo) Sprague-Dawley rats have sub-
stantially less AQP1 expression in CPe than do young
adult counterparts [57]. Accordingly, senescent rats are
less able to form CSF [79]. Human CPe expresses AQP1
[80]. This raises the possibility of therapeutically upregu-
lating or restoring AQP1 expression in aged humans when
the CSF turnover rate is compromised by AD and NPH
[3,19]. Conversely in congenital hydrocephalus it may be
feasible to down-regulate AQP1 expression or channel
activity in CPe, thereby lowering CSFP by suppressing CSF
formation rate [77,78]. Atrial natriuretic peptide (ANP), a
CSF-modulator, has been implicated as a regulator of
AQP1 channel function [69].
2.5 Receptors for neuropeptides
Neuropeptides in CSF stimulate peptidergic receptors in
CP to alter metabolism of 2nd messengers and the associ-
ated ion transport coupled to fluid formation [81].
Choroidal arginine vasopressin (AVP) is functionally
interactive with various fluid-regulating peptides (Table
3). AVP release from CP, for autocrine inhibitory regula-
tion, is promoted by angiotensin (Ang II) and basic
fibroblast growth factor (FGF2). Upon stimulation,
choroidal receptors for ANP and AVP both induce dark
epithelial cells [82,83]in vitro as well as in vivo. Dark CPe
cells have a neuroendocrine role to down -regulate CSF
production. Stimulation of V1 vasopressinergic receptors
induces dark cells [83], reduces Cl- efflux from CPe [83],
and decreases CSF formation [84]. Moreover, ANP tran-
scripts for three natriuretic receptors [85] that generate
cyclic guanylyl monophosphate (cGMP) [86] are
expressed in both intact and cultured CP. In some physio-
logical settings ANP curtails CSF formation by CP [87].
This inhibition may be mediated by CPe dark cells [82]
that are more frequent in hydrocephalus.
Also supporting this fluid homeostasis model are the
observations of substantial plasticity of choroidal recep-
tors for water-regulating neuropeptides when CSF dynam-
ics are imbalanced. There is up-regulated or down-
regulated density of CP receptors for ANP in hydrocepha-
lus [88], depending upon the pathophysiology (kaolin-
induced as well as congenital). CSF neuroendocrine regu-
lation is also reflected by changes in ANP receptor density
secondary to altered CSF hydrodynamics or fluid shifts in
space flight [89]. Moreover there are more choroidal bind-
ing sites for AVP in AD [90], a disorder that can present
with ventriculomegaly [3] and increased CSF pressure
[91]. Peptide analogs of ANP and AVP [17] may prove
beneficial for therapeutically modulating CSF parameters
through action at CP neuropeptide receptors.
3 CSF pressure
CSFP or ICP rises rapidly when there is a significant imbal-
ance between CSF formation and drainage. Augmented
ICP reduces cerebral blood flow (CBF) and oxygenation
and, at the molecular level, may alter protein expression
in neurons and glia. Therefore, because of potentially dev-
astating effects of elevated ICP on brain functions, it is
clinically important to assess factors that regulate CSF
pressure and devise more effective ways to monitor and
manage distorted ICP.
Table 3: Neuropeptides/receptors that regulate CSF formation
ANP AVP ANG II FGF2
Effect on CSF formation after i.c.v. administration of neuropeptide [84, 87, 178, 217] ↓↓↓ ↓
Peptidergic effect on choroidal blood flow [84, 139] ↑↓↓N/A*
Inducer of neuro-endocrine-like dark epithelial cells in choroid plexus? [82, 83, 178] Yes Yes N/A Yes
Choroid epithelial receptors for peptides [83, 85, 103, 211, 217] NPR-A V1 AT1 FGFR2
Concentration of peptide in CSF in hydrocephalus or increased ICP [98–100, 104] ↑↑ N/A N/A
* N/A: Data are not available.Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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3.1 Servomechanism regulatory hypothesis
ICP is a complex function of hydrodynamic and hemody-
namic parameters. In combination they produce, in adult
humans, a CSFP of 100–200 mm H2O measured in the
lateral recumbent position by lumbar puncture. This pres-
sure is directly proportional to the CSF production rate
and outflow resistance, which typically is 70 mm H2O/
ml/min and greater in the 8th decade than in young adults
[92].
On the hydrodynamics side, feedback down regulation of
CSF formation can lower CSFP. Homeostatic adjustments
to decrease fluid output by CP are critical because sus-
tained CSFP elevation compromises the vascular supply to
the CNS [93]. Accordingly, elucidation of neuroendocrine
fluid regulation is essential for developing agents to man-
age CSFP. A key observation for constructing a CSFP regu-
latory model is that the CSF concentration of most
neuropeptides, including ANP, depends upon a central
(CNS) source rather than a peripheral (plasma) source
[94]. Moreover, intraventricularly-administered ANP
reduces CSFP elevated by ischemia [95] or congenital
hydrocephalus [96]. Such findings prompt the pursuit of
various elements comprising a central homeostatic system
to regulate CSFP.
Growing evidence supports a ventricular servomechanism
to stabilize CSFP. One hypothesis posits pressure-sensi-
tive regulatory elements in the CSF-periventricular nexus
that respond by synthesizing/releasing peptides that target
the CP [97]. A prime neuropeptide candidate for acutely
regulating CSFP is ANP. Collective experimental and clin-
ical evidence demonstrates that: i) the CSF titer of ANP
increases proportionally to CSFP elevation [98], ii) the
CSF level of ANP is elevated in high-pressure hydroceph-
alus [99,100], iii) the ANP receptors in CP undergo a
Vmax adjustment to compensate for the CSFP increase in
hydrocephalus [88,101], and iv) the CPe is bioreactive to
ANP [82] and modulates CSF formation [102] by a cGMP-
dependent mechanism [86,103]. The putative regulation
of CP-CSF by ANP and AVP occurs in acute high-pressure
hydrocephalus but evidently not in chronic NPH [104].
Interestingly the CP of immature rats (with a relatively
low CSFP and incompletely-developed CSF secretion
[33]) is less sensitive than the adult epithelium to modu-
lation by ANP and AVP [83]. This is probably due to
infant vs. adult differences in neuropeptide receptor den-
sity and coupling to CPe metabolism.
3.2 Ontogeny of CSF pressure generation
Increasing CSFP during development in rodents is tempo-
rally associated with the early phases of fluid formation by
CP. CSF pressure in pentobarbitone-anesthetized exterior-
ized fetal rats (18–21 days p.c.) is about 20 mm H2O, ris-
ing to 34 mm H20 at 10 days postnatal and later [105].
The 1 – 3-week postnatal interval in the rat is a watershed
period in the maturation of CP-CSF secretion [33,106].
Thus the increasing vascularity and arterial perfusion of
the plexus in early postnatal life [107-109] foster the pro-
gressively increasing enzymatic and transport capabilities
of the CPe [110,111]. Enhanced blood flow and meta-
bolic rate combine to accelerate Na+ and Cl- transport into
ventricles [112]. Such incremental fluid production by CP
[113] elevates CSFP to a level found in adults [105]. Arte-
rial pulsations in CP along with increasing fluid turnover
set up a pressure head for moving CSF down the neuraxis
[114] and developmentally opening up subarachnoid
sites for reabsorption. This increased hemodynamic-
hydrodynamic generation of CSF secretion and pressure
pulse fosters a spurt in brain growth [106-113]. Maintain-
ing appropriate CSFP in the developing CNS critically
depends upon aqueductal patency and smooth CSF flow.
Just as intraocular pressure importantly molds the shape
of the developing eye, the typically-moderate rise in CSFP
in perinatal stages of life [105] contributes to morphing
the expanding CNS.
3.3 Congenital hydrocephalus and periventricular regions
Untoward effects on brain development, however, result
from inordinately elevated CSFP secondary to blockage of
the Sylvian aqueduct. Augmented CSFP has been
observed in aqueduct-impaired hydrocephalic (H-Tx)
rats, increasing 2-fold between 10 and 21 days after birth
[115]. In other H-Tx studies, CSFP increased from about
20 mm H20 at 10 days after birth to as high as 90 mm H20
by 3 weeks [116,117]. Elevated pressure reflects blocked
flow out of the lateral ventricle. The consequent CSF stasis
in hydrocephalus interferes with cerebral and ventricular
system development [118,119].
Transgenic mice lacking ependymal-specific expression of
hydin [120], which facilitates ciliary functions, have gross
distortions in the anatomical relationship between the
ventricles and adjacent brain. Certain hydrocephalic mal-
formations stem from metabolic, transport and ciliary
deficiencies in the developing CP [121]. Systematic inves-
tigations should explore how faulty cilia development in
the choroido-ependymal lining affects CSF formation,
composition, volume and ultimately the CSFP.
CSFP impacts periventricular protein expression and
secretion into the ventricles. An optimally-growing CNS
depends on delicately-balanced biophysical and bio-
chemical phenomena in CSF [6]. In congenital hydro-
cephalus, however, there is not only increased pressure
but also altered CSF composition [118,119,121]. Nerve
growth factor concentration is elevated in CSF of children
with congenital hydrocephalus [122], but cytokine levels
are evidently stable (implying intact BBB function) [123].
Whereas some alterations in CSF constituents are due toCerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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interrupted CSF flow [119,121], other changes in compo-
sition are related to byproducts of pressure-induced oxida-
tive damage to cells near the ventricles [124]. Other
modifications of CSF chemistry in hydrocephalus, possi-
bly homeostatic, may be due to pressure-induced up-reg-
ulation of proteins secreted by CPe, ependyma and
periventricular tissue. One example is choroidal growth
factor synthesis in response to augmented CSFP that fol-
lows ischemia [7] or trauma. CPe and ependyma are a
plentiful source of growth factors [125,126] to repair tis-
sue injured by elevated CSFP and its secondary effects [8].
The interaction between the pressures of the CSF and vas-
cular systems, especially in the onset of hydrocephalus,
awaits systematic investigation. Fascinatingly, the elevated
arterial pressure in spontaneously hypertensive rats is
linked to ventriculomegaly via effects on secretion by the
subcommissural organ (SCO) in the aqueductal wall
[127]. The SCO and its associated Reissner's fiber (RF)
secrete into CSF glycoproteins essential for establishing
normal CSF flow down the neuraxis for distal reabsorp-
tion. Therefore, a disrupted SCO-RF complex results in
less efficient CSF flow and consequent hydrocephalus
[128,129]. Compromised function of the SCO [130] as
well as CP [121] leads to ventriculomegaly and imbal-
anced CSF dynamics. These observations point to the sig-
nificance of the circumventricular organs in secreting
factors to optimize developing CSF flow, volume and
pressure.
3.4 Brain response to elevated CSF pressure
In addition to the pressure effects on the periventricular
zone, there are several ways that CSFP impacts the brain
globally. Responses to elevated CSFP can be broadly cate-
gorized by: i) how neural structure and metabolism are
affected by modified CSF dynamics; and ii) how homeo-
static transport interfaces that protect the parenchyma
respond to neuropeptide up-regulation in CSF hyperten-
sion. For the first consideration, there are marked oxida-
tive changes [131-133] in hydrocephalus that are reflected
in the way that injured neurons metabolize neurotrans-
mitters [134] and myelin [135]. Although beyond the
scope of this review, the topic of deleterious anaerobic
neuronal metabolism in hydrocephalus has been treated
previously [136-138]. Concerning the second considera-
tion, i.e., homeostatic mechanisms, the regulatory
increases in ANP and AVP concentrations in CSF from ele-
vated CSFP [98-100,104] evidently foster vascular per-
fusion of several regions. Even though up-regulated ANP
may decrease CSF formation in ischemia and hydroceph-
alus, it does support CPe viability by increasing choroidal
blood flow [139]. CSF-administered ANP and AVP dilate
cerebral arteries [140,141]. ANP- and AVP-dilating effects
on large pial arteries thereby counter cerebral vasospasm
induced by endothelin following subarachnoid hemor-
rhage [142]. Such perfusion-supporting actions by cen-
trally up-regulated ANP curtail edema [143] by stabilizing
the CP and cerebral vasculature threatened by ischemia
and augmented CSFP.
In chronic hydrocephalus, even moderate increments in
CSFP can compromise CBF and metabolism. Intermittent
changes in CSFP need a thorough analysis, particularly in
regard to effects on regional hydrodynamics and hemody-
namics. Clearly, prospective as well as retrospective stud-
ies [91] on CSFP are essential to advance treatment
strategies for CSF diseases (Fig. 6).
3.5 Advances in measuring CSF waveforms
CSFP wave analysis provides substantial insight on the
state of CSF dynamics and is more reliable than assess-
ments of cerebral perfusion pressure and mean ICP, espe-
cially when there are differences in baseline pressure
[144]. CSF has a characteristic pressure pulse that varies in
health and disease. Cardiovascular parameters markedly
affect CSFP waves by contributing systolic and diastolic
components of pulse amplitude and latency [145-148].
Arterial pressure pulsations are transmitted across CPs to
ventricular fluid [114] and generate CSF pressure waves. It
would be clinically useful in hydrocephalus [149] to char-
acterize these pressure waves in the ventriculo-subarach-
noid system.
How is ICP recorded, and does it matter where sensors are
placed, i.e., in the CSF, brain parenchyma or epidural
space? Continuous ICP signals have been recorded with
sensors such as the Camino OLM ICP and Codman ICP
MicroSensor [144]. A study of brain parenchyma vs. epi-
dural space monitoring revealed marked differences in
recorded mean pressure, but not in the parameters of
mean ICP wave amplitude and mean ICP wave latency
[150]. Thus, epidural ICP recording (to estimate paren-
chymal pressure) is feasible for determining parameters
such as single wave pulse pressure amplitude (dP) and
single wave latency (dT, or rise time). Moreover, monitor-
ing ICP in the cerebral ventricles, as waveform parameters,
gives comparable results to pressure measurements done
with the sensor in brain parenchyma [145]. Evidence is
lacking for an appreciable pressure gradient between the
parenchyma and ventricular CSF.
Pulsatile components of CSFP will likely be more helpful
than mean CSFP in evaluating intracranial compliance
(Fig. 7). Eide introduced a method for continually record-
ing ICP signals at 100 Hz, converting to digital data, and
then processing in 6-s time windows [151]. An algorithm
filters noise prior to accepting cardiac beat-induced single
ICP waves for analysis of amplitude and latency. Wave
amplitude analysis is also promising in pediatric hydro-
cephalus [152] because it is a better predictor of intracra-Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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nial compliance than is mean pressure. Children with
intracranial hypertension from hydrocephalus or cranio-
synostosis had a more successful outcome after surgery if
the mean CSF wave amplitude pre-surgery was > 5 mm Hg
[152]. To assure quality control of the waveforms proc-
essed, an algorithmic analysis screens out infarct-induced
waves to improve diagnostic information [153].
ICP/CSF waveform analyses have predictive potential for
outcome in adult patients with chronic hydrocephalus.
Although patients with idiopathic NPH (iNPH) may have
normal mean ICP, it is possible that they have altered sin-
gle ICP waves. Higher values of mean ICP wave ampli-
tudes were found in iNPH patients who eventually
improved after shunting [154]. In one cohort, the mean
CSFP wave amplitude was a better predictor than resist-
ance to CSF outflow (Ro), in regard to positive clinical
change a year after shunting [155]. Up to 60% of iNPH
patients have augmented mean CSF wave amplitudes, and
90% of these individuals respond favorably to shunting
[156]. Post-shunting cognitive outcomes [157] were bet-
ter in iNPH patients with relatively high pre-operative
mean ICP wave amplitudes (Fig. 7).
The so-called B waves in CSF, especially in NPH patients,
can predict post-surgical outcome in adult chronic hydro-
cephalus. Slow B waves, however, only weakly correlated
with improvement after shunt surgery [158]. An alterna-
Frequency analysis of CSFP in patients with AD vs. AD-NPH syndrome Figure 6
Frequency analysis of CSFP in patients with AD vs. AD-NPH syndrome. AD subjects by NINDS-ADRDA (Alzhe-
imer's Disease and Related Disorders Association) criteria (n = 222) were initially screened to exclude NPH. 181 of these 222 
patients had CSF pressure measurements (supine position). Seven subjects (4%) had a CSFP 220 mmH2O or greater, i.e., higher 
than the mean CSFP of 103 mmH2O for the AD-only group. The 7 subjects with elevated pressure had NPH as well as AD, i.e., 
the NPH-AD syndrome. The larger CSFP peak corresponds to the AD-only group; the smaller peak (higher pressures) per-
tains to AD-NPH hybrids. Reproduced from Silverberg et al [91].Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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tive to B wave examination has been proposed. Accord-
ingly, the relative pulse pressure coefficient (RPPC)
combines the effects of pulsatory volume changes and
elastance on CSFP [159]. RPPC reflects reallocation/stor-
age rather than reabsorption of CSF because it relates
pulse amplitude to mean CSFP.
A worthy clinical goal is to ascertain absolute CSFP by
methodology minimally disruptive to CSF or brain. CSF is
contiguous with fluids in the ear, nose and eyes. The orbit
vasculature, for example, is exposed to ambient CSFP.
This should enable reliable CSFP determination from
transocular sonographic and dynamometric data. An
empirical index based on ocular arterial (blood flow) and
venous (outflow pressure) measurements highly corre-
lates (r = 0.95) with absolute CSFP [160]. Therefore this
promising indirect ocular approach deserves refinement.
Technical advances are also being made with directly
measured CSFP. A novel technique minimizing CNS inva-
sion utilizes a hollow mandrin. This ventricular probe
allows precise cannulation of CSF and determination of
opening CSFP without fluid loss along the penetrating
catheter [161]. This refined mandrin approach consist-
ently accesses the ventricles with a single puncture com-
pared with occasional multiple penetrations in previous
cannulation procedures to locate the CSF [161]. Overall,
the aim of CSFP assessments is reliability by minimally
perturbing the CSF-brain.
To expedite CSF and hydrocephalus modeling, attention
is being devoted to delineating CSFP signals. Highly pre-
cise signals for hemodynamic and hydrodynamic param-
eters facilitate CSFP analyses. Continuous signal inputs to
multiple sensors (blood pressure and CSFP during infu-
sions) are integrated by software [162] to evaluate fluid
dynamics and predict steady-state responses to infusion
tests. Computerized rheoencephalography non-invasively
assesses NPH by analyzing changes in cerebral electrical
impedance related to pulsatile blood flow [163]. Arterial
compliance determined by rheoencephalography is eval-
uated from the regression of arterial pulse amplitude
(aAMP) on mean CSFP. Patients with lower arterial com-
pliance have higher slope values for aAMP vs. CSFP.
Increasingly sophisticated analyses of CSFP against arte-
rial pressure will improve predictive shunting. Models of
fluid-structure interactions to predict pressure and flow
within the ventricles [164] and transmittal of pressure
into brain parenchyma [165,166] are advancing the the-
ory of pulsatile fluid dynamics.
4 CSF flow
CSF flow pathways need elucidation for both healthy and
diseased brain. Choroidally secreted CSF flows down the
neuraxis to the 4th ventricle and then out through hind-
Augmented intracranial pressure wave amplitude in shunt  responders: The difference between shunt non-responders  and shunt responders (i.e., improved CSF dynamics and brain  function) 6–9 months after surgery with regard to preopera- tive mean ICP (P = 0.19) and mean ICP wave amplitude (P =  0.002; based on 1-way ANOVA of 6-sec time window data) Figure 7
Augmented intracranial pressure wave amplitude in 
shunt responders: The difference between shunt non-
responders and shunt responders (i.e., improved CSF dynam-
ics and brain function) 6–9 months after surgery with regard 
to preoperative mean ICP (P = 0.19) and mean ICP wave 
amplitude (P = 0.002; based on 1-way ANOVA of 6-sec time 
window data). Mean wave amplitude was 5 mm Hg in positive 
responders. Reproduced with permission from P. Eide [157].Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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brain foramina into the cisterna magna and the subarach-
noid space in basal regions. In addition to this classically-
described pathway, new evidence indicates that ventricu-
lar CSF also flows by another route to the basal and mid-
brain cisterns, i.e., into subarachnoid extensions [167] of
the velum interpositum (from dorsal 3rd ventricle) and
superior medullary velum (rostral 4th ventricle). Addi-
tional evaluation is needed for the limited CSF flow from
cisterna magna to cortical subarachnoid regions and
arachnoid villi [168], and for the possible shunting of CSF
bulk flow between the ventricles and injured/edematous
brain parenchyma [169]. Insight gained on CSF distribu-
tion routes will benefit pharmaco-therapeutic regimens.
4.1 CSF flow and brain metabolism
There is increasing appreciation that reduced CSF flow
adversely affects brain metabolism and fluid balance
[3,18,19,118,119]. Historically in hydrocephalus investi-
gations, CSF pressure and volume [170-173], not flow
and composition, have been emphasized in animal mod-
els and shunt design. Consequently, considerable knowl-
edge has accrued on pressure-volume relationships in the
ventriculo-subarachnoid system. Evidence continues to
accumulate, however, for the importance of CSF flow on
cerebral metabolism. Because the CP-CSF supplies micro-
nutrients and peptides to neuronal networks, and
removes many catabolites, impeded CSF flow disturbs
metabolism in early life [119] as well as in late stages
[174].
4.2 Flow effects on fetal germinal matrix
Interference with CSF flow through the ventricles and
aqueduct in fetal life profoundly retards brain develop-
ment [118,119]. This is due partly to compromised trans-
port of growth factors from secretory sites such as CP to
subventricular germinative zones where stem cells
become neurons. In the H-Tx hydrocephalic rat there is a
congenital defect leading to tissue dysgenesis in the aque-
ductal region [175,176]. The H-Tx model [117-119] dis-
plays prenatal ventriculomegaly and distortions in CSF
growth factor delivery via volume transmission even
before intraventricular pressure rises. Prenatally-altered
CSF flow thus causes maldevelopment in H-Tx due to
faulty differentiation of neural precursor cells [118].
Because CP function is fundamental for CNS develop-
ment [2], it is pertinent to assess how perturbed CSF flow
and composition harm the growing brain. Non-invasive
quantification of aqueductal CSF flow [177] during peri-
natal life would enhance insights into pediatric hydro-
cephalus.
4.3 Decreasing CSF flow in aging CNS
CSF flow disruption in adult chronic hydrocephalus also
devastates cerebral functions. Throughout aging, the abil-
ity of CP epithelium to manufacture CSF undergoes con-
tinual decline [2,3,57,79]. As CSF formation rate dwindles
by 50% or more in senescence and disease [3,19], the sink
action [33] of slower-flowing CSF is attenuated [9]. The
concentration of potentially-toxic peptides and organic
metabolites in CSF [174] and brain consequently builds
up due to sluggish flow. Less favorable concentration gra-
dients for catabolites diffusing from ISF to ventricular
CSF, results in reduced clearance of harmful substances
from brain. Pharmacological studies in old animals
treated with flow inhibitors, e.g., acetazolamide [36,53],
FGF2 [178,179], and kaolin [180] are needed to analyze
the time course of elevated CSF protein concentration in
acute vs. chronic states of curtailed flow.
4.4 Refinement of non-invasive flow measurements
Due to previous technological limitations, there has been
a paucity of investigations to assess CSF flow in animal
models. However several non-invasive studies involving
magnetic resonance imaging (MRI) to quantify CSF flow
have been carried out in humans. One of the earliest such
analyses by Ridgway et al. [181] demonstrated that CSF
flow is pulsatile, i.e., moving to and fro, alternately in
cephalic and caudal directions. Thus, they used the MRI
pulse sequence (gated from the R-wave of the electrocar-
diogram) to calculate CSF flow velocities (e.g., 2.9 cm/sec)
and corresponding flow rates (e.g., 0.4–0.6 ml/min). Sim-
ilarly, dynamic MRI of CSF flow, using a multi-slice spin
echo approach, was used to compare aqueductal CSF flow
rates before and after ventriculostomy to repair non-com-
municating hydrocephalus [182]. MR phase imaging has
also been used to demonstrate a circadian variation in
human CSF flow, the latter being twice as great at night as
in daytime [183].
Recent advances have been made in the technology and
algorithms for quantifying CSF flow non-invasively.
Using phase-contrast MRI to calculate CSF and CBF curves
over the cardiac cycle, Stoquart-Elsankari et al. [184]
extracted data for several CSF parameters: mean and peak
flows, latencies and stroke volume. They found that CSF
stroke volume was reduced in the elderly, both at the
aqueductal and cervical levels. Another new approach is
the phase contrast balanced steady-state free precession
(PC-bSSFP). It is advantageous over the gradient echo in
that signal-to-noise ratio is improved and non-laminar
CSF flows can be more efficiently analyzed [185]. PC-
bSSFP has been more suitable than the gradient echo
approach for quantifying turbulent CSF flow in the pre-
pontine cistern and cervical subarachnoid space
[184,185]. Application of refined imaging procedures to
small animal models will be helpful in modeling flow
pulsatility and the intra-cardiac cycle displacements of
CSF volume.Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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5 CSF volume
Maintaining normal CSF volume is indispensable to brain
health. CSF volume ranges from the greatly reduced
spaces in slit ventricle syndrome to the ventriculomegaly
of severe hydrocephalus. The dynamics of ventricular con-
traction and expansion are poorly understood but likely
involve the interplay of three main factors: changes in
brain tissue properties (e.g., compliance), CSF dynamics
and vascular parameters. CSF volume can be significantly
altered iatrogenically by suboptimal rate of CSF flow
through shunts. Disorders that rupture the BBB and
BCSFB also modify ventricular volume. Understanding
CSF volume is important because of the impact on neuro-
nal function exerted by changes in cerebral metabolism
and blood flow. Therefore, information is needed on the
rate and extent of regional CSF volume adjustments.
Maintaining the appropriate size of the ventriculo-cister-
nal-subarachnoid compartments is biophysically and bio-
chemically complex. CSF volume in adult mammals
ranges from about 0.04 ml in mice [77] to approximately
150–160 ml in humans [3]. Over an organism's lifespan,
the CSF volume is variably set to a higher or lower degree
in response to stressors. Hypoperfusion of the plexuses
[186-188] interrupts the O2 supply and severely compro-
mises the BCSFB and ventricular integrity. Hyperthermia
also devastates the CP-ventricle nexus. By way of osmotic
and autonomic disruptions between the CP and CSF,
hyperthermia causes an edematous expansion of the CNS
parenchyma [189]. On the other hand, ventricular vol-
ume can contract as occurs in slit-ventricle syndrome
[190]. Transgenic, hydrocephalic and hypertensive mod-
els inform on ontogenetic, physical and physiologic fac-
tors that alter ventricular volume. The discussion below
treats the overlapping actions of vascular, hydrodynamic
and neuroendocrine phenomena in regulating ventricle
size.
5.1 Hemodynamic factors
CSF volume importantly adjusts to physiological varia-
tions in cerebral blood volume (CBV). Thus an increased
amount of blood within the cerebrovascular system leads
to a displacement, and to a reduced volume, of CSF. Con-
versely, a decrease in CBV can result in an augmented vol-
ume of CSF. This more-or-less reciprocal relationship
between CBV and CSF volume reflects the fact that,
according to the Munro-Kelly doctrine [191], the com-
bined volume of blood, CSF and brain remains relatively
constant in the intracranial space bounded by the rigid
skull. Consequently, in order to regulate pressure within
the CNS, the CSF is a useful physical buffer that helps to
accommodate changes in brain blood supply.
Physical aspects of choroidal hemodynamics also signifi-
cantly affect CSF volume. There is a brisk, pulsating blood
flow of 3–4 ml/g/min to the plexus [108,109]. This strong
arterial pulse is transmitted across the choroidal epithelial
membranes to CSF. Therefore nearly all CSF motion is
pulsatile. It has long been known that CSF dynamics are
markedly impacted by vascular pressure waves in CP
[114]. Hyperdynamic upstream CP pulsations dilate the
cerebral ventricles when there is increased impedance to
the flow of CSF pulsations in the SAS [192]. As down-
stream CSF impedance rises, there is redistribution of CSF
pulses from the subarachnoid compartment back to the
ventricles and the capillary-venous circulation. Egnor and
colleagues propose that communicating hydrocephalus
with ventriculomegaly results from pulse redistribution
within the cranial cavity [192].
5.2 Hydrodynamic factors
Hypo-secretion of CSF, presumably occurring consequent
to disrupted bicarbonate transport in CP of SLC4 knock-
out mice, drastically reduces ventricular volume [193]. On
the other hand, hypersecretion of CSF by an actively
metabolizing CP papilloma [194], predisposes to ven-
tricular expansion. Thus, altered transport and permeabil-
ity at the choroidal blood-CSF interface significantly bears
on the ventricular volume.
The spontaneously hypertensive rat model (SHR) also
reveals the significance of BCSFB transport and fluid for-
mation in regulating fluid volume within the CNS inte-
rior. SHR displays a ventriculomegaly [127,195] that
likely results from markedly transformed CP functions.
Ions, water and non-electrolytes more readily penetrate
the blood-CSF barrier of SHR compared with non-hyper-
tensive Wistar-Kyoto (WKY) controls [196]. The CPe of
SHR rats consistently has a greater number of mitochon-
dria, increased Golgi processing and enhanced transport
activity [197]. The higher permeability of the blood-CSF
interface in SHR allows greater penetration of organic sol-
utes such as sucrose from blood to CSF [196]. Increased
activity of the Na+-K+-2Cl- cotransporter [198] which pro-
motes fluid transfer in CP [1], also occurs in SHR. Greater
permeability and secretion at the CP in SHR would pro-
mote faster transfer of fluid into the ventricles. This is con-
sistent with the ventricular expansion in SHR [127,195].
According to the Egnor model [192], the larger pulse
amplitude of the transmitted arterial pulse in the SHR
would also be a factor causing ventriculomegaly.
Other injury models of the blood-CSF barrier shed light
on dysregulated ventricular volume. Acute arterial hyper-
tension in adult rats transiently opens the BCSFB allowing
plasma proteins to leak into the ventricles [199]. Patho-
logical disturbances that enhance CP permeability lead to
macromolecule accumulation in the normally low-pro-
tein CSF. This increases the osmotic pressure of CSF and
draws water into the ventricles. Transient forebrainCerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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ischemia also disrupts choroidal ultrastructure and trans-
porters [187], causing a temporary loss of CSF homeosta-
sis. Further analyses of hypertensive and ischemic insults
to the choroidal circulation should delineate repair mech-
anisms [125] that restore homeostasis of the CPe and ven-
tricular volume.
5.3 Neuroendocrine factors
Peptidergically-regulated fluid transfer at the BCSFB and
BBB [200,201] helps to set the volume and composition
of CSF and brain ISF, respectively. Moreover the fine tun-
ing of fluid exchange at the ependymal interface, medi-
ated by neuropeptides [202] and growth factors [125],
effects fluid balance between the ventricles and intersti-
tium. When these coordinated homeostatic mechanisms
at the transport interfaces are upset, the ventricles can
either expand or contract.
At the blood-CSF interface in CP, there is a complex inter-
play among ANP, AVP and FGF2 and their apical mem-
brane receptors to control ion and water secretion into the
ventricles. This trio of peptides down-regulates CSF for-
mation via neuroendocrine effects on CPe [2,6,17,81-87].
ANP, AVP and FGF2 levels in the CP-CSF system are
mainly under central control [6,98,203-208] and thus
largely independent of plasma and peripheral effects.
When the CNS is perturbed biochemically or physically,
these peptidergic systems are activated to restore normal
hydration and osmolality. By these mechanisms, extracel-
lular as well as intracellular fluid volumes in CNS are sta-
bilized [209].
Ventricle size is affected by peptide regulation of CSF out-
put from CP. FGF2 has many physiological roles, but a
newly appreciated one is fluid regulation. Exogenously
administered FGF2 both in vivo and in vitro reduces CSF
formation [178,179]. This FGF2-induced suppression of
fluid generation is evidently promoted by the choroidal
release of the CSF inhibitor, AVP [210]. FGF2 and AVP
expression in the CPe, like that of the hypothalamus-pitu-
itary axis, is sensitive to the water balance of the organism
[208,211]. It is intriguing that in the growing SHR the
continually declining FGF2 level in CPe (and perhaps a
resultant diminishing inhibitory tone on CSF production)
is temporally associated with progressively increasing ven-
tricle size [195]. Collective evidence implicates choroidal
FGF2 in ventricular volume regulation.
ANP is also regarded as a volume-regulating peptide
[212]. Several investigators report that choroidal ANP
receptors in the ventriculomegalic SHR rat are down regu-
lated [103,213-216]. Therefore, the reduced ANP tone
lowers the generation of the CSF-inhibiting second mes-
senger, cGMP, in the CPe of SHR [103]. A downloader of
extracellular fluid volume in peripheral systems, ANP may
have a similar function in the CNS. ANP receptor impov-
erishment in the CP of SHR rats [103,213-216] may cause
less inhibition of CSF production and the related ability to
maintain normal ventricular volume. Accordingly, the
observed increase in CSF formation in the SHR [196], pos-
sibly due to attenuated natriuretic modulation, would be
consistent with ventriculomegaly. The question is begged
as to whether a genetic alteration in the ANP (or related
neuroendocrine) systems in SHR rats precludes CSF vol-
ume down-regulation.
To construct a global model of CSF-ISF volume homeos-
tasis, more information is needed on how ANP, AVP and
FGF2 work in concert to regulate fluid transfer across CP
and BBB [200,201,209]. AVP also interacts with angi-
otensin II in the CP-CSF system to decrease fluid produc-
tion [217]. Neuropeptidergic modulation at fluid
reabsorption sites in the CNS importantly awaits elucida-
tion. Gaining insights on peptidergic regulation of CSF
flow in various regions may make feasible the use of nat-
ural ligands or their analogs and antagonists [17] to ther-
apeutically correct aberrant ventricle size.
6 CSF turnover rate
The brain's ability to turn over or renew CSF is crucially
important in maintaining metabolic balance in the CNS.
This is because the brain lacks lymphatic capillaries. It
therefore relies heavily on continual CSF convection to
clear macromolecules and catabolites from the neuronal
environment. Such clearance deficiency, as in states of
CSF stagnation when turnover rate is severely compro-
mised, results in catastrophic changes in the composition
of the interstitium, vessel walls and meninges. Conse-
quently, neurons incur damage. Pharmacotherapeutic
strategies to stabilize the aging CNS might well include
ways to maintain CSF formation and prevent ventricular
enlargement.
The CSF turnover rate is defined as the volume of CSF pro-
duced in 24 hours divided by the volume of the CSF space.
In young adult rats, the total CSF volume is renewed
about 11 times daily compared to 4 times/day in control
humans (Table 4). Moreover, in both rodents and man,
the rate of turnover of CSF declines with age and dementia
progression (Table 4). Such dwindling of the CSF turno-
ver rate is partly due to the declining ability of CP to form
CSF in later stages of life [18,79].
6.1 Adverse effects of ventriculomegaly
Another substantial factor in turnover rate is the volume
of CSF. In young adults, there is a CSF space of 150–160
ml and a formation rate of about 0.4 ml/min [3]. The
result is a normal turnover rate in man of about 4 volumes
of CSF per 24 hours (Table 4). CSF volume or space how-
ever is augmented in senescence and dementia, often asCerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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an ex vacuo hydrocephalus secondary to atrophic loss of
brain mass. Large ventricles inherently impair the CSF's
ability to efficiently renew itself because turnover rate is
inversely related to CSF volume (ventricles, cisterns and
subarachnoid spaces). Accordingly, in aging, NPH and AD
(Table 4), the CSF turnover rate can fall by 3–4-fold. Con-
sequently as the ventricles enlarge in aging and disease
[3], the purity of CSF is gradually lost due to less rapid
turnover causing stagnation of extracellular fluid.
6.2 Attenuated CSF sink action
CSF disorders in both the young and old CNS often
involve impoverished fluid turnover. CSF sink action to
remove catabolites is a function of fluid formation and
CSF volume relative to brain volume. In perinatal devel-
opment when BCSFB transport capacity is less, the CP
forms fluid at a slower rate per mass of tissue than in
adults [33,106,107,110-113]. Moreover, in early life the
ratio of CP-CSF volume to brain volume is relatively high
[34]. These factors lessen the capability of immature brain
to eliminate unneeded catabolites. The growing anabolic
brain requires an optimally functioning CP-CSF to
remove catabolites as well as provide micronutrients.
Congenital hydrocephalus, with expanding ventricles, fur-
ther reduces the already low degree of CSF sink action in
the fetus [33,113]. Consequently, the low CSF turnover in
infantile hydrocephalus makes the maturing CNS espe-
cially vulnerable to damage.
In later life, CSF turnover rate is also markedly curtailed
[2,3,9,18,19,79]. In senescence, NPH and AD, there is
progressively lower CSF formation rate and expanded ven-
tricular volume. The net result for all three states is dimin-
ished CSF turnover rate (Table 4). Such attenuated CSF
sink action in aging, NPH and AD [3,19] alters CSF com-
position (see below) with deleterious consequences for
brain. In aging, when dwindling fluid percolation and
interstitial deposits hamper clearance of brain solutes, the
curtailed flux of neurotransmitter metabolites (such as
homovanillic acid) from interstitium to ventricles [218]
likely reflects diminished bulk flow and diffusion
between ISF and CSF. In a rat model that mimics NPH
[219], beta amyloid peptide (Aβ) accumulates centrally as
in NPH patients. In both cases Aβ clearance pathways are
impaired (Fig. 8), by reduced transport of low-density
lipophilic protein receptor related protein (LRP-1) at the
BBB [219] and slower bulk flow from attenuated CSF
dynamics [3,79]. Pharmacological intervention
[11,12,15-17] in geriatric patients to maintain CSF forma-
tion and minimize ventricular dilation might prevent cur-
tailed CSF turnover. A worthy goal is to provide trophic
drugs or CP transplants [12,15] to minimize neurodegen-
eration by stabilizing CSF volume and content.
7 CSF composition
Historically, CSF compositional analyses have been used
widely to monitor distortions in brain metabolism, evalu-
ate disruptions of barrier transport and permeability func-
tions, obtain pharmacokinetic parameters for drugs
targeting the brain parenchyma, and identify biomarkers
for aiding the diagnosis and prognosis of CNS diseases.
Thus the CSF contains valuable biochemical and cellular
information that can be advantageous for more effective
clinical management of brain complications. An appreci-
ation of altered CSF composition, especially in relation to
corresponding changes in plasma, is particularly useful in
interpreting scientific and neurological data.
7.1 Kidney-like action of CP-CSF system
The brain vitally depends upon the stability of CSF com-
position [220], similar to the way the body is dependent
on plasma chemistry that is stabilized within tolerable
limits. Acting like a kidney inside the CNS [34], the CP has
a major role in homeostatically adjusting the brain extra-
cellular fluid [1,18,27]. CSF constituents are exquisitely
regulated by a complex array of transporters in the CP epi-
thelium [1,18,46,68,220,221]. Substantial deviations in
CSF concentration of ions and peptides require restora-
tion to normality [17]. When CSF homeostasis fails, neu-
ronal function becomes vulnerable [18,19,222]. A major
translational challenge is to correct CSF solute distortions
in aging, NPH and AD when both CP and BBB transport
Table 4: CSF dynamics and volume in aging and neurodegeneration
Rat Aging* Human Disease†
3 mo 19 mo 30 mo Normal NPH AD
CSF Formation Rate (ml/min) 0.00121 0.00148 0.00065 0.40 0.25 0.20
CSF Volume (space) (ml) 0.156 0.196 0.308 150 300 250
CSF Turnover Rate (volumes/day) 11 10.8 3.0 4 1.2 1.2
* CSF formation rate and volume in rats were determined by indicator dilution during ventriculo-cisternal perfusion [79]. CSF turnover rate = 
formation rate/volume.
† CSF formation rate and volume in patients were quantified by a modified Masserman technique [3]. NPH, normal pressure hydrocephalus; AD, 
Alzheimer's disease.
Volumes/day = the number of times each day that the entire CSF volume is renewed.Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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capacities are diminished [3,9,18,79,219,223]. Stabilizing
the CSF composition is predicated largely on pharmaco-
logical manipulation of the barrier transporters and on
restoration of a breached BCSFB or BBB [223-225]. To
help manage certain CSF disorders, aberrant concentra-
tions of proteins [226] and catabolites [174] in CSF need
to be profiled and categorized for various stages of NPH
and AD.
7.2 Altered CSF biochemistry in aging and disease
Biochemical analysis of the CSF has immense potential
for diagnostics and prognostics [227]. In disease states the
CSF composition is transformed by invading immune
cells, plasma cytokines and pathogens [5]; as well as by
modified active secretions from CP. Therefore the CSF is
clinically useful to evaluate: i) the nutritional and trophic
status of the brain in patients with hydrocephalus or
dementia [228]; ii) the purifying capacity of central anion
and peptide reabsorptive systems in aging and AD [229],
iii) the therapeutic or cytotoxic concentration of certain
CSF-borne agents targeted to neurons or meninges [230],
and iv) the presence of abnormal solutes [231], or normal
molecules in atypical concentrations. Solute concentra-
tion profiles can define certain disease states and be used
to evaluate the benefit of therapeutic intervention.
To sustain the brain, the CSF provides a full complement
of vitamins, peptides, nucleosides and growth factors
[1,2,10,27,222,232]. Adequate nutritional/trophic sup-
port of neurons via CSF is compromised in senescence
[79]. This may result from dietary deficiency coupled with
reduced micronutrient delivery to brain by inefficient CP-
CSF transport mechanisms [18,57,223]. Vitamins B and C
are transported specifically across CP to CSF and adjacent
neural tissue [222-234]. In aging, massive interstitial
fibrosis of CP (Fig. 9) and oxidative damage to the epithe-
lium [223] impair this essential transport route. Structural
and biochemical disruptions may reduce not only CSF
formation rates, but also the secretion of organic sub-
stances into CSF of AD subjects [228]. Overall then, CSF
concentration data for the elderly should be interpreted in
light of reduced bulk flow as well as altered metabolism
[218].
Proteins in CSF can also become deficient in late life.
Transthyretin (TTR) is extensively synthesized and
secreted by CP into CSF. TTR is a useful CSF marker
because it is manufactured mainly by CP [235] and only
slightly if at all, by brain parenchyma [236]. One function
of TTR is to bind Aβ, thus stabilizing it in a soluble form
and preventing CNS peptide toxicity [223] that may occur
when Aβ self-assembles into neurotoxic oligomers. CSF
levels of TTR decrease in both aging and AD [237,238]. A
CSF deficiency of TTR may predispose the brain intersti-
tium to Aβ oligomer toxicity and plaque formation [223].
Strategies are needed to sustain TTR secretion by CP in the
elderly, e.g., by nicotinic modulation [239]. Moreover the
array of growth factors secreted by CP helps to repair inju-
ries from forebrain ischemia or neurodegeneration
[7,17,125,126]. Brain fitness requires a sustained choroi-
dal secretion of a cocktail of peptides and proteins that
effect a balanced metabolic homeostasis of the CSF and
neuronal-glial networks.
Decreased expression of LRP-1 transporters in cortical ves- sels of rats with chronic hydrocephalus Figure 8
Decreased expression of LRP-1 transporters in corti-
cal vessels of rats with chronic hydrocephalus. A. 
Immunostaining (bold arrows) of lipoprotein receptor-
related protein-1 (LRP-1) in endothelial membranes of sec-
tioned capillaries and arterioles in cerebral cortex of 
Sprague-Dawley rats (1-year control) B. Attenuated LRP-1 
staining (negative vessels surrounded by asterisks) after 6 wk 
of hydrocephalus induced by kaolin injection into cisterna 
magna. Findings suggest reduced Aβ removal from cortex to 
blood in chronic hydrocephalus. Bar = 50 μm. Images repro-
duced with permission from NeuroReport [219].Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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In addition to receiving productive secretions from the
CP, the CSF is also a repository for catabolites diffusing
out of brain. Excessive metabolite efflux from ISF to ven-
tricles can toxify the CSF. Toxic catabolites in CSF, gener-
ated by peroxidative phenomena, increase with age and
neurodegeneration [174]. Glycated proteins in CSF are
elevated in AD [231]. The CP tissue that protects and
nourishes the CSF-brain nexus, suffers from oxidative
injury and disrupted metabolism in advanced age and AD
[18,223,240,241]. A vicious cycle ensues as toxic neuronal
products (e.g., Aβ) enter CSF from brain and inflict further
harm to the CP already debilitated by aging [57,79]. The
steady build up of Aβ in CP epithelium may disturb leptin
transport from blood to CSF [242]. Such altered transport
at the BCSFB could perturb neuroendocrine balance by
interfering with hormone signal transfer to hypothalamus
via the CSF.
7.3 Importance of clearance transport
Maintaining ISF and CSF compositional purity is of prime
importance and depends upon efficient clearance mecha-
nisms. Because the CNS lacks lymphatic capillaries, the
CSF-mediated removal of metabolites and toxins is essen-
tial for efficient neuronal function. The CP-CSF system,
proximally and distally, plays a major role in removing
harmful substances. This occurs three ways. First, reab-
sorptive transporters in the apical membrane of CP epi-
thelium actively remove organic anions and peptides
from ventricular CSF [1,17,243]. This choroidal clearance
complements active reabsorption of unneeded metabo-
lites from ISF into cerebral capillaries [229]; for a given
catabolite, the proportional clearance across BBB vs.
BCSFB [244] should be determined in both health and
particular diseases. Secondly, the continually-elaborated
nascent CSF streams through the brain interior acting as a
sink for metabolites diffusing down concentration gradi-
ents into the ventricles [1-3,33]. These substances pass
through the ventriculo-subarachnoid system by bulk flow
to distal drainage sites [1,18]. A third aspect of toxin clear-
ance is the downstream extrusion of metabolites via out-
ward CSF flow at the arachnoidal-lymphatic-venous
interfaces [1,7,245]. In healthy CSF these three disposal
mechanisms work in concert to effect fluid homeostasis.
Therefore, in chronic hydrocephalus (NPH) with
decreased CSF turnover [3,19], distorted CSF chemistry
may be rectified by enhancing CSF formation, flow and
drainage. Metabolite clearance defects and toxicity must
be considered along with known ischemic insults in NPH
to obtain a complete picture of chronic hydrocephalus.
Comprehensive analysis of CSF biochemistry helps to
manage NPH, AD and other complications of senescence.
Several animal models demonstrate inhibitory effects of
neuropeptides and growth factors on CSF formation and
reabsorption [178,246]. A logical extension is to analyze
systematically the biochemistry of human CSF at stages of
chronic hydrocephalus with and without neurodegenera-
tion. CSF profiling of protein, peptides and organic
metabolites (e.g., sphingomyelin derivatives) in aging
patients will likely provide insight on how the failing bar-
riers and brain metabolism are linked to deficient CSF
dynamics. Elevated levels of ventricular CSF albumin,
neuropeptide Y, vasoactive intestinal peptide and sul-
fatide (an ischemia marker for subcortical arteriosclerotic
encephalopathy) have negative implications for surgical
outcome by shunting [247,248]. Systematic analyses of
CSF constituents in progressive iNPH and aqueductal ste-
nosis [247] will likely improve predictive power for shunt-
ing benefits.
7.4 Therapeutic manipulation of composition
Pharmacological manipulation of CSF and brain ISF com-
position may prove feasible. One goal is to improve CSF
Fibrosis in senescent rat choroid plexus Figure 9
Fibrosis in senescent rat choroid plexus. Aging takes a 
toll on choroid plexus, functionally and structurally. This 
electron micrograph depicts massive collagen deposits in CP 
interstitium, i.e., between the vascular core and outer epithe-
lial (E) ring. Fibrotic (F) bands in a 36-mo-old Brown-Nor-
way/Fischer rat are 40–50 times thicker than corresponding 
collagenous layers in young adults. Excessive fibrosis likely 
impedes nutrient flow from plasma to ventricles and reab-
sorption of Aβ peptide fragments from CSF. Fibrosis in aging 
and AD also occurs in the arachnoid [240]. Consequently, 
fibrosis interferes with CSF dynamics via multiple effects. 
Appreciation is extended to P. McMillan for electron micros-
copy. Scale bar = 2 μm.Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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flow and content through actions of drugs delivered
across the BCSFB into the brain interior [16,17]. Repara-
tive agents are needed in periventricular regions (e.g., the
subventricular zone, hippocampus and white matter)
damaged by elevated CSFP [91], ischemia
[7,126,186,187] and distorted CSF chemistry. Another
compelling need is to develop CSF-cleansing procedures
for geriatric patients in whom brain fluid turnover is seri-
ously compromised. This would be analogous to renal
dialysis in patients with kidney failure. Novel technology
for CSF dialysis or low-flow shunting, in particular sub-
groups of patients with dementia, may improve cogni-
tion. Therefore, the use of new drugs [16] and
biotechnological devices [15] deserves consideration, to
slow down degeneration or promote healing of NPH/AD.
CPs and ventricles [16,17] show promise as regulatory
sites to attain desired drug concentrations and optimize
CSF composition [249].
8 CSF recycling in relation to ISF dynamics
Functional interactions between CSF and ISF are plentiful.
CSF and ISF move by bulk flow, the former through large
cavities and the latter finely through narrow winding
pathways in the neuropil and grossly along myelinated
fiber tracts. Fluid is convected into and out of the brain
parenchyma, depending upon prevailing local hydrostatic
pressure gradients. Knowledge of bulk flow pathways is
important for: the delivery of micronutrients and peptides
to neurons and glia, the conveyance of hormone signals to
target cells, the delivery of drugs to receptors, and the
removal of catabolic products from CNS. Pathological
sequelae ensue when ISF and CSF do not freely percolate.
CSF movement via interstitial pathways requires further
analysis due to disease implications.
8.1 CSF exchange with brain interstitium
CSF and ISF dynamically exchange water and solutes
across the ependymal (interior) and pia-glial (exterior)
surfaces of brain [1,27]. Brain ISF has distinctive circula-
tory features [22]. Continual ISF turnover, even at a rela-
tively slow rate [250,251], maintains an optimal
microenvironment for neurons. In aging there is less effi-
cient active transport at the brain capillary endothelium
and choroidal epithelium. Consequently, the slower turn-
over of ISF and CSF causes CNS accumulation of poten-
tially injurious organic acids and peptides. Neurons are
harmed in senescence when metabolites accumulate
interstitially [9].
8.2 Components of ISF movement in brain
Metabolic waste is discarded through ISF and CSF clear-
ance routes. Brain ISF conducts metabolites away from
neurons and glia to excretory sites. ISF has multiple input
and output components that keep the fluid mixed and
delivered to excretory loci. On the input side of ISF vol-
ume and flow is a CSF-like fluid likely secreted by the
astroglial-endothelial complex in microvessels [252]. The
putative BBB fluid production is much less than by CP.
Another input to ISF is water generated by parenchymal
metabolism [252]. A third input to ISF is a fraction of the
SAS fluid (originally derived from the CP-ventricular
nexus) that enters cortex via the Virchow-Robin perivascu-
lar spaces [253-255], propelled in part by the pumping
action of arteries and arterioles. As such, this recycled CSF
likely drains back into the ventricles.
ISF output has at least two components. First, quantita-
tively substantial reabsorptive fluxes of solutes (e.g., Aβ
peptides) occur via LRP-1across endothelial cells into vas-
cular lumina [229]. As LRP-1 expression at the BBB wanes,
as with age, the CP LRP-1 transporter may need to cover
this deficit in clearance in brain capillaries by reabsorbing
proportionally more Aβ at the BCSFB. Another class of
solutes reabsorbed across BBB is organic acids/anions,
actively removed from brain to blood by the organic
anion transport system (OATS) [256]. Secondly, there is
bulk flow and diffusion of substances from ISF to large-
cavity CSF [22] that are ultimately reabsorbed at arachnoi-
dal sites. Studies are needed to determine how the propor-
tion of catabolite clearance, at BBB vs. BCSFB and bulk
flow, changes with progression of brain pathology. Fluid
percolation through brain interstices [251] is substantially
slower than CSF circulation through ventriculo-subarach-
noid spaces. ISF bulk flow with its entrained catabolites
awaits comprehensive characterization, particularly in
regard to ISF interaction with the water dynamics of CSF.
8.3 Compromised ISF/CSF dynamics and amyloid retention
Volume transmission of ISF and CSF is substantially atten-
uated in aging and dementia [3,9]. Brain catabolites build
up when fluid turnover rates fall by > 50% [19]. An exam-
ple is Aβ40, generated by enzymatic cleavage of amyloid
precursor protein [229]. Due to deteriorating fluid
dynamics, Aβ accumulates in ISF and perivascular spaces
during aging, NPH and AD. Our working model is that
central Aβ clearance is compromised by interacting factors
in aging. By nine months in the mouse there is reduced
efflux transport of radiolabeled Aβ1-40 [229], perhaps
due to decreased LRP-1 transport at the abluminal inter-
face of the BBB. LRP-1 loss would result in slower removal
of Aβ from ISF [229], causing Aβ42 to accumulate in cor-
tical microvessels [257]. Moreover, attenuated CSF forma-
tion reduces ventricular sink action [33] that draws (by
concentration gradients directed into CSF) Aβ fragments
and other peptides from ISF. Another unfavorable out-
come in senescence is Aβ42 accumulation in CP epithe-
lium, ependyma and arachnoidal cells [257]. These CSF-
bordering interfaces control fluid movement among CNS
compartments [1]. When burdened with toxic Aβ, the
choroido-meningeal tissues are probably less effectiveCerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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homeostatically in stabilizing brain ISF against plaque
formation.
Cumulative evidence for dwindling transport and fluid
dynamics in aging, NPH, and AD, [3,19] points to com-
mon vulnerabilities in the degenerating BCSFB [18] and
BBB [224]. Hydrocephalus induced in old rats by kaolin
injection causes Aβ retention in many CNS regions [219].
A unified model for brain proteinopathies should relate
peptide/protein distribution kinetics to fluid-turnover
capacities. ISF functional integrity relies upon an efficient
CP-CSF system and healthy cerebral microvessels. Follow-
ing a late-life breakdown of transporters, the brain inter-
stitium accumulates catabolite debris, including peptide
fragments. This predisposes to concentration-dependent
Aβ self-assembly into oligomers, fibril formation and
plaque deposition. Information is needed on how Aβ
retention alters CBF, arteriolar actin [258], hydraulic con-
ductivity of ISF, tortuosity of extracellular channels and
viscoelasticity of the matrix. These factors impact the
interactive ISF-ventricular fluid dynamics and hence the
delivery of catabolites to excretory pathways.
9 CSF reabsorption
CSF clearance into lymph and blood involves diverse ana-
tomical sites and physiological mechanisms. Disrupted
CSF reabsorption is a common cause of hydrocephalus.
The eventual resolution of clinical hydrocephalus
depends upon knowledge of outflow sites and their regu-
lation. When CSF is retained in the CNS, compensatory
mechanisms stabilize ICP [97]. In addition to cranial
nerve outflow adjustments, there are spinal nerve arach-
noidal pathways that facilitate fluid egress following CSF
retention in the spinal SAS. Moreover, when CNS is fluid
overloaded, the brain capillaries may use up regulated
AQP channels to absorb ISF under high pressure.
Improved understanding of fluid reabsorption at multiple
sites will lead to better management of CSF and ISF con-
gestion.
9.1 Arachnoidal outflow resistance
CSF Ro has been the key hydrodynamic parameter to eval-
uate reabsorptive phenomena. Methodologically, CSF
infusions accompanied by CSFP measurements have gen-
erated ample Ro data for humans and animals [259]. In
rodents, Ro is elevated in congenital hydrocephalus
[115,260] and NPH-like states [178]. CSF Ro increases
two- to three-fold in patients with NPH [261]. The elegant
work of Jones and colleagues in rats [105,262] demon-
strated that in normal CSF development, the Ro to CSF
reabsorption across the transverse sinus decreases
between 10 and 20 days postnatal, i.e., when upstream
CSF secretion increases [33,113]. However, in hydro-
cephalic H-Tx rats, Ro (from lateral ventricle) increases
after birth due to aqueduct occlusion [115] but does not
decrease in later development as in non-hydrocephalic
controls. Recently, Eklund and colleagues [259] reviewed
important applications of Ro data derived from CSF infu-
sions.
9.2 Arachnoid villi vs. olfactory drainage routes
There has been lively debate regarding the main site of
CSF reabsorption. The past decade witnessed a gradual
paradigm shift on the preponderant site of CSF drainage
in several animal models. Accordingly, drainage/reab-
sorption of CSF via the olfactory [263] and optic nerves
[264], cribriform plate, nasal submucosa and cervical
lymphatics is now regarded as the primary bulk flow pas-
sageway for extruding subarachnoid CSF from the brain of
rats, pigs and sheep [265-272]; and even in a non-human
primate [269]. Microfil injection studies by Johnston and
colleagues provide substantial evidence that CSF flow into
nasal lymph is the major route of CSF egress in several
species [266]. The prevailing view is that lymphatic vessels
external to the cranium receive a large volume of CSF in
many mammals (Fig. 10); however, humans have yet to
be evaluated in vivo. This new emphasis on drainage via
the olfactory route [265-272], rather than by arachnoid
villi, culminates a century-long notion that CSF and
lymph have a functionally intimate association.
Until recently, CSF drainage models have emphasized a
substantial role for the arachnoid villi embedded in the
dura mater of the superior sagittal sinus. Each arachnoid
villus was thought to have a one-way (CSF outward)
valve-like mechanism that opened in response to a posi-
tive hydrostatic pressure gradient between CSF and dural
venous blood [252]. It now appears that in most mam-
mals the arachnoid villi normally are not the locus of
most CSF reabsorption, but under conditions of elevated
CSFP may mediate an increasing amount of CSF clearance
[267]. In man, the physiological role of arachnoid villi in
the setting of healthy CSF dynamics awaits characteriza-
tion, as do the precise mechanisms of CSF flow along cra-
nial nerves to the eyes and nose. Large Pacchionian
granules in CSF of humans [252], compared to diminu-
tive arachnoid villi in rodents, suggest the former may
play a relatively greater role in CSF reabsorption in man.
Johnston and colleagues have implicated the cribriform
plate above the nose as a key extracranial site in CSF out-
flow. Assessments of proportional flow through cribri-
form and non-cribriform routes indicate that at low ICP
the CSF absorption occurs mainly across the plate [269].
Thus an experimentally sealed cribriform plate is useful
for evaluating CSF hydrodynamic parameters under con-
ditions of blocked CSF flow into the nasal submucosa and
cervical lymphatics. An obstructed cribriform plate sub-
stantially reduces CSF clearance, increases ICP [270] and
impairs regulatory systems that compensate for CSF vol-Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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ume infusions [269]. At least in sheep, the abovemen-
tioned global CSF parameters for late gestation resemble
those in adults [271], including the relative non-involve-
ment of arachnoid villi vs. the more functional olfactory
drainage pathways [272]. Brinker et al. [273], using mag-
nification radiography during infusion of adult rats, ear-
lier demonstrated a significant rapid drainage of CSF via
the olfactory, optic and cranial nerves (VII and VIII) into
cervical lymph.
Reabsorbed CSF ultimately drains into venous blood.
Therefore, venous occlusion experiments provide clues on
the relative contribution of particular CSF-venous inter-
faces to CSF reabsorption. Hydrocephalus (CSF retention)
has been associated with impaired extracranial venous
obstruction [274]. Collectively, such observations point
to olfactory/cervical lymphatic drainage, rather than
arachnoid villi, as the primary mechanism of normal CSF
drainage [245]. Moreover, arachnoid villi and granula-
tions may serve as an ancillary CSF drainage route (by
opening one-way valves) when ICP rises substantially.
This fits earlier observations of hydrostatic pressure gradi-
ent-dependent bulk flow across arachnoid villi [252] and
the formation of fluid-filled vesicles in arachnoid epithe-
lium under elevated pressure. Pore-like openings were
observed in a thin neurothelial layer along the optic nerve
extending into the lymphatics [275]. Promising investiga-
tions of human arachnoidal granulations in vitro (Fig. 11),
CSF reabsorption routes in the adult rat as revealed by recovered 125-labeled human serum albumin (HSA) in lymph nodes:  Anesthetized male adult Wistar rats (n = 8) were killed 6 hr after 125I-HSA injection into lateral ventricle Figure 10
CSF reabsorption routes in the adult rat as revealed by recovered 125-labeled human serum albumin (HSA) in 
lymph nodes: Anesthetized male adult Wistar rats (n = 8) were killed 6 hr after 125I-HSA injection into lateral ventricle. HSA 
uptakes were averaged for bilateral and multiple nodes. Symbols indicate differences (P < 0.05) in test node activity relative to 
spleen (*) or popliteal (#) lymph nodes. Head and lymph node activities greater than spleen indicate tracer passage from CSF 
directly to submaxillary or cervical nodes. Lumbar node activity was above the spleen and popliteal nodes (not expected for 
direct CSF drainage). Reproduced with permission from M. Johnston and the American Journal of Physiology [268].Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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utilizing chamber and cell culture preparations such as
those devised by Grzybowski et al. [276,277], should elu-
cidate fluid transport across hydrostatic pressure-sensitive
pores. Answers are needed for key questions: How do
arachnoid cell pore-like structures respond biophysically
(ultrastructurally) to elevated CSF and/or venous pres-
sure? Also how are the biochemical secretions of the
arachnoid membrane altered by intracranial benign
hypertension or hydrocephalus? Biophysical and bio-
chemical data for cranial as well as spinal CSF reabsorp-
tion await integration.
9.3 Fluid reabsorption along spinal nerves
CSF reabsorption also occurs along spinal nerves. Radio-
nuclides injected into the CSF in a cisternography study of
human reabsorption revealed a 20% reduction of radioac-
tivity in the spinal subarachnoid space during one hour of
testing [278]. This spinal CSF clearance was enhanced in
physically active (vs. resting) individuals. When hydro-
cephalus was induced in adult rats by cisternal kaolin
injection, resulting in blocked cranial absorption of CSF,
there was compensatory fluid clearance along lumbo-sac-
ral rootlets [279]. In another kaolin study producing
hydrocephalus/syringomyelia in rats, high-molecular
weight ferritin traced the bulk CSF passage from the cen-
tral canal, across ruptured ependyma and dorsal columns,
and then along spinal nerves into extradural lymphatic
vessels [280]. Such compensatory spinal CSF outflow
might be particularly significant in upright humans [280].
9.4 Reabsorption across capillary aquaporin channels
Hydrocephalus impacts and is impacted by CSF egress.
When increased Ro causes central fluid overloading, there
may be alternate non-arachnoidal mechanisms activated
by augmented ICP to prevent further build up of CSF and
ISF. Water channel AQPs at the blood-CSF [78] and
blood-brain interfaces are significant control points to
regulate fluid movements. AQPs 1 and 4, respectively, are
expressed in CP and brain microvessels. When cranial
nerve outlets, arachnoid villi and spinal nerve reabsorp-
tive mechanisms are overwhelmed by extra fluid, com-
pensatory changes in AQP expression may participate in
ICP adjustments. Thus, the elevated CSFP attending
hydrocephalus (in both kaolin-induced and the H-Tx
genetic anomaly), leads to augmented expression of
AQP4 [281-283]. A key question is whether up regulated
AQP4 in hydrocephalic brain enhances ISF reabsorption
into capillaries. On the other hand, when AQP1 at the
BCSFB is down regulated, there is less fluid input to the
CNS because CSF formation is reduced and ICP conse-
quently lowered [77,78]. Altered AQP expression at the
barriers implies that water fluxes via channels that contact
ISF and CSF can be pharmacologically regulated to reme-
diate brain fluid imbalance secondary to faulty reabsorp-
tion.
10 Developing translationally effective models 
for restoring CSF balance
Restoration of fluid balance perturbed in congenital and
adult chronic hydrocephalus remains an enormous chal-
lenge. Translational progress is difficult because CSF is
complexly interactive with many fluid compartments and
interfaces (Fig. 1). In elucidating CSF dynamics, it is
imperative to analyze not only the CP-CSF-arachnoid
nexus [284] but also the brain capillary-ISF-ependymal
nexus. A thorough understanding of fluid transfer from
brain to CSF to lymph, or in the reverse direction during
Immunostaining of cytoskeletal and junctional proteins in cul- tured human arachnoid granulation epithelial cells Figure 11
Immunostaining of cytoskeletal and junctional pro-
teins in cultured human arachnoid granulation epi-
thelial cells. A. Expression of intermediate filament protein 
vimentin (Cy3 conjugated anti-vimentin antibody). B. Expres-
sion of cytokeratin (FITC conjugate to broad spectrum anti-
cytokeratin antibody). C. Expression of connexin43 (FITC 
conjugate); punctate distribution at borders (red arrows) 
points to gap junctions in cell culture. D. ZO-1 (tight junc-
tion) staining (FITC conjugate) at cell-cell borders (white 
arrow) demarcates overlapping filapodia (short linear struc-
tures in parallel). E. Expression of desmoplakin (with Alexa 
Fluor 555 conjugated secondary antibody) reveals desmo-
somes along adjacent cell borders (white arrows). F. Expres-
sion of E-cadherin, an epithelial-specific cell adhesion 
molecule, at periphery of cells (white arrows) in a pattern 
similar to that of connexin43 and ZO-1. All images have 
same scale (bar = 50 μm). Reproduced with permission of 
Holman et al [277].Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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elevated-pressure hydrocephalus (from CSF to ISF to cere-
bral capillary blood), should expedite therapy with drugs
or fluid-drainage hardware.
The CPs are more than an appendage of the BBB [1].
Rather, the composite BCSFB is a major interface that,
when functioning in parallel with the cerebral capillary
network (Fig. 12), effects a stable extracellular environ-
ment for neurons at optimal volume, composition and
pressure. Having a renal-like function to stabilize fluid in
the CNS [34], the CP protects the brain just as the kidney
safeguards peripheral organs by stabilizing the plasma
constituents. To maintain CNS stability, is there physio-
logical cross talk or signaling between BBB and BCSFB?
Probably so, but multi-compartmental analyses are neces-
sary to answer this question.
An altered BCSFB can affect the BBB, and vice versa. The
actions and responses at these primary transport interfaces
are addressed with in situ and in vivo models allowing con-
current analyses of barriers not possible with in vitro and
cell culture preparations. One approach is multi-compart-
mental analysis [112] or simultaneous microdialysis
[285] of brain (parenchymal probe) and CSF (cisternal
microprobe), following systemic administration of radi-
otracers [286]. Another tack is regional immunohisto-
chemical analyses of peptide, channel or transporter
expression in CP, brain capillaries, ependyma, neurons
and arachnoid [219]. Systemic analysis of solute and
water transfer enlightens the magnitude and vector of
fluid shifts. Furthermore, Western blot, ELISA and PCR
data from isolated CP and brain microvessels furnish
complementary data [257] to characterize in vivo transport
mechanisms.
A fascinating advance for CSF modeling is that the BCSFB
and BBB can be involved in opposite responses. This hap-
pens when the CNS adapts to altered fluxes of water and
peptides (e.g., resulting in Aβ retention) in diseases that
physically impair distribution pathways. Table 5 shows an
overview of the compensatory adjustments for aging,
NPH and AD in regard to water and peptide translocation
at blood-CNS interfaces. First, in regard to water move-
ment through channels (Table 5A), there is normally net
Concerted transport at blood-brain and blood-CSF barriers: Cerebral capillaries and choroid plexuses transport different  materials [16, 17, 27, 34] Figure 12
Concerted transport at blood-brain and blood-CSF barriers: Cerebral capillaries and choroid plexuses transport dif-
ferent materials [16, 17, 27, 34]. Although there is transport overlap, the BBB largely supplies brain with glucose, amino acids, 
free fatty acids (FFA) and peptides, whereas BCSFB furnishes the CSF-brain nexus with vitamins, growth factors and proteins 
such as transthyretin. CNS fluid balance results from regulated water transport across AQP4 at BBB and AQP1 in BCSFB. The 
reabsorptive transporters LRP-1 and P-glycoprotein (Pgp) are expressed differentially in BBB [225, 229] and BCSFB [291]. Both 
interfaces have to be analyzed to characterize phenomena such as Aβ deposition in interstitium. To understand brain fluid 
composition and barrier interaction pathophysiologically, it is advantageous to analyze BBB and BCSFB concurrently.
MAJOR  TRANSPORT  INTERFACES  in  CNS
 Bidirectional Transport at Barriers:
Inward Secretion & Outward Reabsorption
Arterial
Inflow
Venous
h
Blood-CSF Barrier
Blood-Brain Barrier
Interstitial Homeostasis
Endothelial transport: glucose, amino acids, FFA; peptides
Epithelial transport: growth factors; vitamins B & C; hormones
Outflow
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diffusion of water from blood to brain. In high-pressure
hydrocephalus, however, there may be net reabsorption
of fluid from ISF to capillary blood via up-regulated AQP4
channels. However, such a reversal phenomenon in the
BBB as well as down-regulated AQP1 and CSF formation
in hydrocephalus, need to be demonstrated functionally.
Moreover, Aβ clearance from brain ISF to blood via capil-
lary LRP-1 is evidently decreased in aging, NPH and AD,
but may be increased or maintained in the reabsorptive
CSF-CP nexus where LRP-1 is up-regulated or sustained in
these three states (Table 5B). This postulate awaits proof
from kinetic experiments. Still, mounting evidence indi-
cates that the BCSFB and BBB are complexly interactive
physiologically and in pathologic states. By integrating
data for CP, ependyma, arachnoid and BBB vasculopathy,
insight will be gained on how CSF-ISF dynamics impacts
brain integrity [287].
11 Conclusion
CSF integrates a multiplicity of functions for the CNS.
From fetal life through adulthood, and extending into ter-
minal stages, CP-CSF actively engages in building, main-
taining and repairing the brain [288]. Efficient CSF
homeostatic mechanisms are vital to neuronal networks.
CSF dys-homeostasis in aging and illness, however, can
compromise motor functions and cognition. Stabilizing
or restoring BCSFB and BBB functions in senescence and
disease challenges the next generation of investigators.
Clinical translation of fluid homeostasis concepts is con-
tingent upon expanded knowledge of the multiple trans-
port interfaces that contact CSF.
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Table 5: Differential expression of water channels and peptide transporters at the BCSFB and BBB: Implications for CNS fluid and 
peptide homeostasis
A
Aquaporin 1 (Blood-CSF Interface) Aquaporin 4 (Blood-Brain Interface)
AQP1 is present at the CSF-facing pole of choroid plexus epithelium [70 
– 73, 77, 78], and in the CSF-brain ependymal lining [281].
AQP4 is located in astrocytic foot processes at the BBB. It is associated 
with fluid transfer across cerebral microvessels.
Reduced expression in choroid plexus is associated with slower rates of 
CSF secretion and thus decreases ICP [77, 78].
Elevated expression of AQP4 in the BBB occurs in chronic 
hydrocephalus [281 – 283]; may be associated with fluid reabsorption.
Attenuated expression in aging [57] and in Alzheimer's disease is 
accompanied by slower fluid turnover rate [79].
Diminished expression at BBB leads to a reduction in brain edema 
formation in some animal models.
B
LRP-1 (Low density lipophilic receptor associated protein) RAGE (Receptor for advanced glycation end products)
Expressed in choroidal epithelium and capillary endothelium [229, 257]. Expressed in choroidal epithelium and brain capillary endothelium [257].
Removes Aβ peptide from CSF and brain ISF [229, 243] for excretion via 
blood.
Transports Aβ from blood into brain ISF where the retained peptide 
may predispose to Aβ plaque formation in the interstitium.
Sustained or increased expression in choroid plexus during aging, NPH 
and AD.
Enhanced expression of RAGE at BBB in aging, NPH [219] and AD [225] 
may destabilize BBB and precipitate plaque.
Decreased expression of LRP-1 at the BBB in aging, NPH and AD likely 
interferes with Aβ removal [219, 225, 229].
Expression of RAGE is generally opposite to that of LRP-1 at the 
barriers and in neurons [225].Cerebrospinal Fluid Research 2008, 5:10 http://www.cerebrospinalfluidresearch.com/content/5/1/10
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